# Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction

> **NCT02923128** · PHASE4 · COMPLETED · sponsor: **Zhejiang Cancer Hospital** · enrollment: 240 (actual)

## Conditions studied

- Postoperative Cognitive Dysfunction
- Postoperative Delirium

## Interventions

- **DRUG:** Dexmedetomidine
- **DRUG:** Sufentanyl
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT02923128
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02923128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02923128, "Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02923128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*